多羟基苯基和异羟肟酸衍生物的抗疟活性。
Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives.
作者信息
Holland K P, Elford H L, Bracchi V, Annis C G, Schuster S M, Chakrabarti D
机构信息
Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, Florida 32611, USA.
出版信息
Antimicrob Agents Chemother. 1998 Sep;42(9):2456-8. doi: 10.1128/AAC.42.9.2456.
Abstract
Several known mammalian ribonucleotide reductase inhibitors featuring a polyhydroxyphenyl and/or hydroxamate moiety as the active group were screened for potency in inhibiting growth of the malaria parasite Plasmodium falciparum. Compounds containing a 2,3- or 3,4-dihydroxyphenyl group as well as benzohydroxamate appear to be the most effective inhibitors of the malaria parasite.
摘要
筛选了几种已知的以多羟基苯基和/或异羟肟酸酯部分为活性基团的哺乳动物核糖核苷酸还原酶抑制剂，以检测其对疟原虫恶性疟原虫生长的抑制效力。含有2,3-或3,4-二羟基苯基以及苯甲异羟肟酸酯的化合物似乎是最有效的疟原虫抑制剂。
相似文献
1
Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives.多羟基苯基和异羟肟酸衍生物的抗疟活性。
Antimicrob Agents Chemother. 1998 Sep;42(9):2456-8. doi: 10.1128/AAC.42.9.2456.
2
New ribonucleotide reductase inhibitors with antineoplastic activity.
Cancer Res. 1979 Mar;39(3):844-51.
3
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.含苯并噻唑基的异羟肟酸类组蛋白去乙酰化酶抑制剂的抗疟活性
Antimicrob Agents Chemother. 2008 Oct;52(10):3467-77. doi: 10.1128/AAC.00439-08. Epub 2008 Jul 21.
4
Structure-activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase.核糖核苷酸还原酶的苯甲羟肟酸抑制剂的构效关系
J Pharm Sci. 1980 Jul;69(7):856-7. doi: 10.1002/jps.2600690731.
5
Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.通过优化S1口袋相互作用得到的恶性疟原虫M1和M17氨肽酶的强效双重抑制剂。
Eur J Med Chem. 2016 Mar 3;110:43-64. doi: 10.1016/j.ejmech.2016.01.015. Epub 2016 Jan 13.
6
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.hHDAC6的普鲁卡因胺- SAHA融合抑制剂可对抗耐多药疟原虫。
J Med Chem. 2021 Jul 22;64(14):10403-10417. doi: 10.1021/acs.jmedchem.1c00821. Epub 2021 Jun 29.
7
8
The Diverse Binding Modes Explain the Nanomolar Levels of Inhibitory Activities Against 1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase from Exhibited by Reverse Hydroxamate Analogs of Fosmidomycin with Varying -Substituents.不同的结合模式解释了具有不同取代基的磷霉素反向异羟肟酸类似物对1-脱氧-D-木酮糖5-磷酸还原异构酶所表现出的纳摩尔级抑制活性水平。
Molecules. 2024 Dec 28;30(1):72. doi: 10.3390/molecules30010072.
9
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.3,4-二羟基苯氧肟酸和3,4-二羟基苯甲脒肟对L1210细胞生长抑制机制的研究
Adv Enzyme Regul. 1991;31:71-83. doi: 10.1016/0065-2571(91)90009-b.
10
Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.双管齐下的策略：新型系列异羟肟酸类抑制剂对恶性疟原虫 M1 和 M17 金属氨基肽酶的双重抑制作用。
J Med Chem. 2014 Nov 13;57(21):9168-83. doi: 10.1021/jm501323a. Epub 2014 Oct 24.
引用本文的文献
1
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.疟疾及其共进化遗传疾病镰状细胞贫血的同时辅助治疗。
Blood Adv. 2023 Oct 10;7(19):5970-5981. doi: 10.1182/bloodadvances.2022009124.
2
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.羟基脲治疗与撒哈拉以南非洲镰状细胞贫血儿童疟疾发病率降低有关。
Blood. 2023 Mar 23;141(12):1402-1410. doi: 10.1182/blood.2022017051.
3
Targeting the proteome and organelles for potential antimalarial drug candidates.针对蛋白质组和细胞器寻找潜在的抗疟药物候选物。
Heliyon. 2022 Aug;8(8):e10390. doi: 10.1016/j.heliyon.2022.e10390. Epub 2022 Aug 24.
4
Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.血吸虫嘧啶代谢：与其他寄生虫的比较及潜在化疗靶点的探索
Comp Biochem Physiol B Biochem Mol Biol. 2017 Nov;213:55-80. doi: 10.1016/j.cbpb.2017.07.001. Epub 2017 Jul 21.
5
Protein phosphorylation during Plasmodium berghei gametogenesis.伯氏疟原虫配子发生过程中的蛋白质磷酸化
Exp Parasitol. 2015 Sep;156:49-60. doi: 10.1016/j.exppara.2015.05.010. Epub 2015 May 22.
6
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.二缩二没食子酰基白藜芦醇，一种新型白藜芦醇类似物，能抑制人胰腺癌细胞的生长。
Invest New Drugs. 2013 Oct;31(5):1115-24. doi: 10.1007/s10637-013-0009-x. Epub 2013 Aug 14.
7
Bench scale production of benzohydroxamic acid using acyl transfer activity of amidase from Alcaligenes sp. MTCC 10674.用 Alcaligenes sp. MTCC 10674 中的酰胺酶的酰基转移活性在实验台上生产苯甲羟肟酸。
J Ind Microbiol Biotechnol. 2013 Jan;40(1):21-7. doi: 10.1007/s10295-012-1206-x. Epub 2012 Oct 16.
8
Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access.了解不同自由基清除剂与核糖核苷酸还原酶 M2（hRRM2）结构域的分子相互作用：打开大门并进入。
J Comput Aided Mol Des. 2012 Jul;26(7):865-81. doi: 10.1007/s10822-012-9581-y. Epub 2012 May 26.
9
Activity of hydroxyurea against Leishmania mexicana.羟基脲对墨西哥利什曼原虫的活性。
Antimicrob Agents Chemother. 2008 Oct;52(10):3642-7. doi: 10.1128/AAC.00124-08. Epub 2008 Aug 11.
10
Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine.四种疟原虫天冬氨酸蛋白酶在恶性疟原虫的食物泡中具有活性，其中包括一种具有活性位点组氨酸的蛋白酶。
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):990-5. doi: 10.1073/pnas.022630099. Epub 2002 Jan 8.
本文引用的文献
1
Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum.恶性疟原虫细胞周期调控酶核糖核苷酸还原酶亚基基因的克隆与特性分析
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12020-4. doi: 10.1073/pnas.90.24.12020.
2
Transgenic mouse model of pharmacologic induction of fetal hemoglobin: studies using a new ribonucleotide reductase inhibitor, Didox.胎儿血红蛋白药理学诱导的转基因小鼠模型：使用新型核糖核苷酸还原酶抑制剂Didox的研究
Am J Hematol. 1994 Feb;45(2):136-41. doi: 10.1002/ajh.2830450208.
3
4
Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.化疗药物对哺乳动物细胞中核糖核苷酸还原酶的调控。
Adv Enzyme Regul. 1980;19:151-68. doi: 10.1016/0065-2571(81)90014-5.
5
6
2-Acetylpyridine thiosemicarbazones. 12. Derivatives of 3-acetylisoquinoline as potential antimalarial agents.2-乙酰吡啶硫代半卡巴腙。12. 3-乙酰异喹啉衍生物作为潜在抗疟药
Arzneimittelforschung. 1986;36(1):10-3. doi: 10.1002/chin.198619236.
7
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.双嘧达莫的1期及药代动力学研究：一种核糖核苷酸还原酶抑制剂
Br J Cancer. 1988 Jul;58(1):70-2. doi: 10.1038/bjc.1988.164.
8
Ribonucleotide reductases.核糖核苷酸还原酶
Adv Enzymol Relat Areas Mol Biol. 1990;63:349-419. doi: 10.1002/9780470123096.ch6.
9
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.一项关于通过36小时静脉输注给予双多西的I期和药代动力学研究。癌症研究运动I/II期临床试验委员会。
Br J Cancer. 1990 Mar;61(3):447-50. doi: 10.1038/bjc.1990.98.
10
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
J Med Chem. 1979 May;22(5):589-92. doi: 10.1021/jm00191a027.
Zotero 插件